Aggressive Prostate Cancer at Presentation Following Solid Organ Transplantation

Singh, Zorawar; Holt, Sarah K.; Gore, John L.; Nyame, Yaw A.; Wright, Jonathan L.; Schade, George R.

doi:10.1016/j.euros.2022.03.001

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 76%

“…A few recent studies using Surveillance, Epidemiology, and End Results (SEER)‐Medicare data found that solid organ transplant recipients, including those with KT, are not at increased risk either for developing PCa or for dying from PCa, compared to non‐transplanted men. 19 , 20 , 21 Transplant recipients in these population‐based cohorts, such as our study, face two detection biases. They would have been screened at higher rates prior to and after transplant, which would have decreased and increased the risk of PCa posttransplant, respectively, and must have confounded the results.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Treatment patterns and survival of low and intermediate‐risk prostate cancer in end‐stage kidney disease: A retrospective population cohort study

et al. 2023

View full text Add to dashboard Cite

Background:In accordance with guidelines, observation with or without active surveillance for low-risk prostate cancer increased in recent years in the general population. We compared treatment patterns and mortality for low-and intermediate-risk prostate cancer and mortality rates among end-stage kidney disease (ESKD) and non-ESKD patients.Methods: This is a retrospective population-based observational cohort study of Surveillance, Epidemiology, and End Results-Medicare data of men aged 66 years and older with localized prostate cancer (2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015). ESKD status was determined using Medicare billing codes. Multivariable logistic regression models and Cox-proportional hazards models were used to study definitive treatment patterns and mortality, respectively.Results: For low-risk prostate cancer, dialysis patients (N = 83) had lower but not statistically significant odds (OR, 0.74; 95% CI: 0.48-1.16) of receiving definitive treatment than non-ESKD patients (N = 24,935). For those with intermediate-risk prostate cancer, dialysis patients (N = 254) had lower odds to receive definitive treatment (OR, 0.54; 95% CI: 0.42-0.72) than non-ESKD patients (N = 60,883). From 2004-2010 to 2011-2015, for patients with low-risk prostate cancer, while the receipt of definitive treatment for non-ESKD patients trended down from 72% to 48%, it trended up for dialysis patients from 55% to 65%. Kidney transplant patients (N = 33 for low-risk and N = 91 for intermediate-risk) had lower rates of definitive treatment for low-risk and similar rates of treatment for intermediaterisk prostate cancer compared to non-ESKD patients. Conclusions:The disparity in definitive treatment rates for low-risk prostate cancer among dialysis patients exists despite their high mortality, compared to the general population. Received definitive treatment 48 (57.8) 16 (48.5) 16,174 (64.9) 0.059 176 (69.3) 73 (80.2) 49,029 (80.5) <0.01 Abbreviations: ESKD, end-stage kidney disease; SEER, surveillance, epidemiology, and end results; SD, standard deviation. a Age is expressed as mean and standard deviation. Other variables are percentages. b Low risk: T stages T1c and T2a, Gleason score of 6 or less, and serum PSA level of ≤10 ng/mL and intermediate risk: T stages T2b and T2c, Gleason score of 7, and serum PSA level of 10-20 ng/mL. c Analysis of Variance for Age differences and chi-square test for all the other variables. d Cardiovascular disease includes history of acute myocardial infarction, stroke, congestive heart failure, ischemic heart disease, or atrial fib.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 97%

Treatment patterns and survival of low and intermediate‐risk prostate cancer in end‐stage kidney disease: A retrospective population cohort study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…PSA values may increase by 10% in the post-HD period secondary to the hemoconcentration mechanism. Therefore, obtaining PSA before HD should be considered (7). One of the case reports presented a patient, followed up with half dose (80mg/day) enzalutamide due to side effects such as skeletal pain and anorexia.…”

Section: Discussionmentioning

confidence: 99%

Hemodiyalize Giren Prostat Kanserli Hastada Enzalutamid ile Uzun Süreli Yanıt

BAŞCI>

Ekinci²,

ATEŞ>

et al. 2022

Journal of Contemporary Medicine

View full text Add to dashboard Cite

Current therapies in oncology that offer a longer and better quality of life are leading to more cases where cancer and chronic diseases coexist. Enzalutamide, a second-generation anti-androgen agent, was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There is no series with many patients on the use of enzalutamide in patients with end-stage renal disease (ESRD). We present a patient diagnosed with mCRPC who was followed up with enzalutamide treatment for about 5 years after progression with docetaxel and who was on hemodialysis 3 days a week.

show abstract